导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.48% | 3922/4773 |
| 近一周 | -3.15% | 3775/5462 |
| 近一月 | -3.20% | 1606/5421 |
| 近一季 | -1.89% | 1095/5209 |
| 近半年 | -5.16% | 2764/4920 |
| 近一年 | -15.68% | 3712/4366 |
| 近两年 | 28.67% | 2332/2954 |
| 近三年 | 9.40% | 1756/2253 |
| 成立以来 | -22.49% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.14% 4624/4961 |
8.60% 2577/5312 |
- - |
- - |
| 2025 | 4.07% 3075/4813 |
-6.62% 3375/3635 |
4.20% 831/4076 |
11.21% 3191/4524 |
-3.83% 3343/4813 |
| 2024 | 26.80% 214/3463 |
-4.67% 1736/2808 |
-8.14% 2171/3014 |
39.55% 64/3129 |
3.76% 770/3463 |
| 2023 | 4.88% 212/2656 |
3.77% 1129/2280 |
-1.35% 477/2385 |
7.14% 60/2515 |
-4.38% 997/2655 |
| 2022 | -25.01% 1283/2207 |
-17.79% 1263/1919 |
1.79% 1420/2016 |
-15.24% 1248/2113 |
5.73% 443/2208 |
| 2021 | -0.87% 765/1822 |
-14.17% 1170/1255 |
7.94% 658/1330 |
5.12% 292/1466 |
1.79% 798/1822 |
| 2020 | 24.01% 641/1250 |
-9.82% 723/1028 |
11.16% 744/1067 |
21.01% 44/1164 |
2.23% 1003/1184 |
| 2019 | 46.14% 140/1092 |
47.01% 14/754 |
-6.75% 520/804 |
-3.88% 747/850 |
10.91% 90/918 |
| 2018 | -23.96% 309/834 |
- - |
- - |
- - |
-0.87% 5/691 |
| 2017 | -11.34% 543/714 |
- - |
- - |
- - |
- - |
| 2016 | -17.09% 395/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华安中证全指证券公司ETF联接A VS. 长安沪深300非周期A(740101) |